Adaptimmune Therapeutics plc
ADAP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $26 | $41 | $91 | $117 |
| Short-Term Investments | $0 | $19 | $60 | $69 |
| Receivables | $29 | $21 | $16 | $39 |
| Inventory | $11 | $12 | $7 | $2 |
| Other Curr. Assets | $12 | $11 | $13 | $18 |
| Total Curr. Assets | $78 | $103 | $188 | $244 |
| Property Plant & Equip (Net) | $47 | $49 | $51 | $65 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $4 | $4 | $4 | $4 |
| Long-Term Investments | $2 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $2 | $3 | $4 |
| Total NC Assets | $53 | $55 | $58 | $73 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $131 | $158 | $246 | $317 |
| Liabilities | – | – | – | – |
| Payables | $9 | $6 | $9 | $9 |
| Short-Term Debt | $9 | $9 | $9 | $8 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $11 | $12 | $12 | $19 |
| Other Curr. Liab. | $22 | $24 | $34 | $27 |
| Total Curr. Liab. | $52 | $51 | $65 | $63 |
| LT Debt | $44 | $44 | $70 | $70 |
| Deferred Rev, NC | $101 | $96 | $96 | $99 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $4 | $4 | $4 | $5 |
| Total NC Liab. | $150 | $144 | $170 | $174 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $23 | $23 | $24 | $25 |
| Total Liabilities | $202 | $196 | $234 | $237 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $2 | $2 | $2 | $2 |
| Retained Earnings | -$1,172 | -$1,142 | -$1,094 | -$1,020 |
| AOCI | -$11 | -$4 | -$2 | -$5 |
| Other Equity | $1,109 | $1,106 | $1,106 | $1,103 |
| Total Equity | -$71 | -$37 | $12 | $80 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $131 | $158 | $246 | $317 |
| Net Debt | $27 | $12 | -$12 | -$38 |